Efficacy and safety of peginterferon alpha‐2a/ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C

Njouom, Richard; Sartre, Michèle Tagni; Timba, Isabelle; Nerrienet, Eric; Tchendjou, Patrice; Pasquier, Christophe; Rousset, Dominique

doi:10.1002/jmv.21319

Cited by 12 publications

(23 citation statements)

References 38 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results were in agreement with the studies carried at University of Southampton [37]. Further more in both regimens HCV genotype 2, had a higher ETR than genotype 1 and 4 which same as previous study was carried in Cameroon [38]. However, both therapeutic regimens were less effective in patients infected with HCV genotype 1 and 4 although much higher ETR rates are reached in individuals infected with genotype 2.…”

Section: Discussionsupporting

confidence: 91%

“…Other studies have shown no differences in the clinical response of patients infected with HCV genotype 2 and 3, when they were treated with PEG INF alfa2a or INF alfa combination therapies [38,39]. The SVR of Peg INF based regimen was higher than INF based Regimen in all genotypes except for genotype 4 because as 11 patient infected with this genotype had ETR of Peg INF miss the follow up and thus excluded for the data analysis.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya

Daw¹,

Elasifer²,

Dau³

et al. 2013

Virol Discov

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) therapy has been evolved over years and many parameters were used to evaluate such therapy particularly genotyping. In North Africa and Eastern Mediterranean the genotypes vary from most of world and rarely studies were conducted to assess the influence of such genotypes on the HCV therapy. Aims: This study was designed to determine; the role of HCV genotyping in assessing the efficacy of interferon therapy and to analyze the rates of sustained virological response (SVR) in INF and PegIFN-based regimens according on HCV genotype infecting Libyan patients with chronic hepatitis C infection. Methods: A total of 479 patients with chronic HCV registered at Tripoli Medical Centre were treated with 'INF alfa or PEG-INF-Pegylated INF alfa 2a in combination with ribavirin' for a five year period. These patients were registered and followed up from January 2007 to October 2012. The information were reviewed and data were collected from each patient regarding age, gender, ALT level, and viral load, viral genotype using qualitative PCR. The statistical analysis were carried using SPSS version 11.5. Results: Of the patients studied 86 patients were treated with INF based regimen, only 54% of them had end treatment response (ETR) and 28% had SVR. Off 143 patients treated with peg-INF alfa 2a based therapy; 69% had ETR and 36% had SVR. The SVR of Peg-INF based regimen was higher than INF based regimen in all genotypes except for genotype 4. The relationship between SVR and gender was significant in patients who were given INF based therapy comparable to PEG INF based regimen, though the relationship between SVR and age, basal viral load and basal ALT were also reported in both regimens. Conclusions: HCV genotyping has been found to play an important valuable role in determining the efficacy of Hepatitis C therapy. SVR vary according to the HCV genotype involved. HCV genotype 1 and 4 were found to be the prevalent resistant genotypes infecting Libyan patients. Such findings are particularly important in guiding the clinical therapy of patients infected with hepatitis C virus.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 86%

The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya

Daw¹,

Elasifer²,

Dau³

et al. 2013

Virol Discov

View full text Add to dashboard Cite

show abstract

“…The majority of studies (40/51, 78%) originated from the Middle East[10–13, 15, 16, 18, 27, 28, 34, 35, 37, 40–42, 45, 46, 53–56, 59, 62, 63, 66, 67, 69, 72, 75, 78, 80, 81, 83–85, 88, 91, 95] and Europe (9/51, 18%)[14, 38, 39, 65, 71, 76, 79, 93, 96]. One originated in Cameroon[77] and one multi-center study was conducted in 19 countries[73]. Most studies were performed in a university setting and had an ITT analysis.…”

Section: Resultsmentioning

confidence: 99%

Meta-analysis

Yee

Nguyen

Zhang

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be ~20–70%. However, many of these studies are limited by different study designs and small sample sizes. Aim Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative fashion. Methods A comprehensive literature search in MEDLINE and EMBASE for ‘genotype 4’ was conducted in November 2013. Abstracts from AASLD, APASL, DDW, and EASL in 2012/2013 were reviewed. Inclusion criteria were original studies with ≥25 treatment-naïve HCV-4 patients treated with PEG IFN+RBV. Exclusion criteria were co-infection with HIV, HBV, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (p-value <0.05) and I-squared statistic (>50%). Results We included 51 studies (11,102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% (95% CI: 50–55%) (Q-statistic = 269.20, p<0.05; I2 = 81.43). On sub-group analyses, SVR was significantly associated with lower viral load, OR 3.05 (CI 1.80–5.17, p<0.001); mild fibrosis, OR 3.17 (CI 2.19–4.59, p<0.001); and favorable IL28B polymorphisms, rs12979860 CC versus CT/TT, OR 4.70 (CI 2.87–7.69, p<0.001), and rs8099917 TT versus GT/GG, OR 5.21 (CI 2.31–11.73, p<0.001). Conclusions HCV-4 patients treated with PEG IFN+RBV may expect SVR rate of ~50%. Lower viral load, mild fibrosis, and favorable IL28B (rs12979860 CC and rs8099917 TT) are positively associated with SVR.

show abstract

“…Au Maroc et en Tunisie, avec une prévalence variant de 30 à 66 %, le génotype 1 est le plus fréquent [15][16][17]. Avec des taux pouvant atteindre les 13 %, l'Égypte a la prévalence la plus élevée au monde pour le génotype 4 ; génotype également prédominant au Zaïre, au Gabon, au Cameroun et en Tanzanie [18][19][20][21][22]. Dans la littérature [6,7] Anémie ≤ 9 g/dl Hémoglobine 2 (11,1) > 9 g/dl Hémoglobine 6 (33,3) Neutropénie 1 000 à 750/mm 3 11 (61,1) < 750/mm 3 6 (33,3) Thrombopénie ≤ 100 000/mm 3 2 (11,1) > 100 000/mm 3 12 (66,6) besoin d'être confirmés par des études ultérieures sur des effectifs plus importants.…”

Section: Bithérapie Interféron Pégylé-ribavirineunclassified

Hépatite C chronique: épidémiologie, diagnostic et traitement au CHU Yalgado-Ouédraogo de Ouagadougou

Sombié

Bougouma

Somda

et al. 2010

J Afr Hepato Gastroenterol

View full text Add to dashboard Cite

Notre travail a pour but d'étudier les aspects épidé-miologique, diagnostique et thérapeutique de l'hépatite C chronique. Patients et méthodes : Il s'agit d'une étude clinique prospective réalisée, d'octobre 2005 à décembre 2009, dans le service d'hépatogastroentérologie. Ont été inclus les patients anti-virus de l'hépatite C (VHC) et ARN-VHC positifs. La quantification de l'ARN-VHC a été réalisée par PCR en temps réel. Les malades ont été traités par la combinaison interféron pégylé alfa-2a et ribavirine.Résultats : Au total, 46 patients ont été inclus dont 30 hommes (65,2 %). L'âge moyen était de 47 ans. L'hépatite C a été découverte à l'occasion d'un bilan de santé (37 %), d'une cytolyse (34,8 %), d'un don de sang (15,2 %). Cinq patients (10,9 %) avaient des antécédents de transfusion sanguine. L'examen physique était normal chez 42 patients (91,3 %), quatre patients (8,7 %) avaient une cirrhose. La charge virale moyenne était de 960 978 UI/ml (5,9 log). Les géno-types 1, 2 et 5 ont été retrouvés avec une prédominance du type 2 (71,1 %). Dix-huit patients naïfs ont été traités. Tous génotypes confondus, la réponse virologique soutenue (RVS) a été de 81,2 % dont 92,3 % pour le génotype 2. Trois cas de rechute et deux arrêts de traitement à cause d'effets secondaires sévères ont été observés. La baisse du taux d'hémoglobine a été en moyenne de 3 ± 1,7 g/dl. Une neutropénie inférieure à 750/mm 3 a été observée chez six patients (33,3 %). Deux patients ont présenté une thrombopénie inférieure ou égale à 100 000/mm 3 (11,1 %). La dose d'interféron pégylé a été réduite chez huit patients (44,4 %), celle de la ribavirine chez quatre (22,2 %). Une dépression a été diagnostiquée chez trois patients (6,5 %). Pour citer cette revue : J. Afr. Hépatol. Gastroentérol. 5 (2011).Mots clés Hépatite C chronique · Épidémiologie · Diagnostic · Traitement · Burkina Faso · Afrique de l'OuestAbstract The aim of this study was to describe epidemiological, diagnosis and therapeutic aspects of chronic hepatitis C. Patients and methods: It is a clinical prospective study carried out from October 2005 to November 2009 in the Hepatogastroenterology Department of Yalgado-Ouédraogo Teaching Hospital in Ouagadougou. We included patients with HCV antibodies and HCV-RNA positive. The quantification of HCV-RNA was done in real-time PCR. Treatment regimen was a combined therapy using peginterferon alfa-2a plus ribavirin. Results: A total of 46 patients were enrolled, among whom 30 were men (65.2%). The mean age was 47 years. Circumstances of finding out chronic hepatitis C were: medical check-up (37%), increased transaminases (34.8%) and blood donation (15.2%). Five patients (10.9%) had a history of blood transfusion. Physical examination was normal in 42 cases (91.3%), and we found out cirrhosis in 4 patients (8.7%). The mean viral load was 960,978 IU/ml (5.9 log). The genotypes of HCV were 1, 2 and 5, with a predominant genotype 2 (71.1%). Eighteen patients who had not previously been treated underwent combination therapy. R. Sombie (*) 09 BP ...

show abstract

Efficacy and safety of peginterferon alpha‐2a/ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C

Cited by 12 publications

References 38 publications

The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya

The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya

Meta-analysis

Hépatite C chronique: épidémiologie, diagnostic et traitement au CHU Yalgado-Ouédraogo de Ouagadougou

Contact Info

Product

Resources

About